Drug Profile

PTD 003

Alternative Names: PTD-003; Recombinant decorin - Phoenicis Therapeutics

Latest Information Update: 31 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Phoenicis Therapeutics
Class Antihyperglycaemics; Hepatoprotectants; Recombinant proteins; Skin disorder therapies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

21 Sep 2022 Phoenicis Therapeutics plans a phase II trial in Epidermolysis bullosa dystrophica in 2022 (Phoenicis Therapeutics website, September 2022)
21 Sep 2022 Preclinical trials in Epidermolysis bullosa dystrophica in USA (Parenteral) before September 2022 (Phoenicis Therapeutics pipeline, September 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com